Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Enovis Corporation before investing.

In this article, we go over a few key elements for understanding Enovis Corporation’s stock price such as:

• Enovis Corporation’s current stock price and volume
• Why Enovis Corporation’s stock price changed recently
• Upgrades and downgrades for ENOV from analysts
• ENOV’s stock price momentum as measured by its relative strength

About Enovis Corporation (ENOV)

Before we jump into Enovis Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Want to learn more about Enovis Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Enovis Corporation.

Enovis Corporation’s Stock Price as of Market Close

As of April 29, 2026, 10:46 AM, CST, Enovis Corporation’s stock price was $22.900.

Enovis Corporation is down 2.14% from its previous closing price of $23.400.

During the last market session, Enovis Corporation’s stock traded between $22.530 and $23.290. Currently, there are approximately 57.21 million shares outstanding for Enovis Corporation.

Enovis Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Enovis Corporation Stock Price History

Enovis Corporation’s (ENOV) price is currently up 0.66% so far this month.

During the month of April, Enovis Corporation’s stock price has reached a high of $27.040 and a low of $22.140.

Over the last year, Enovis Corporation has hit prices as high as $37.850 and as low as $21.000. Year to date, Enovis Corporation’s stock is down 14.04%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Enovis Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 28, 2026, there was 1 analyst who downgraded Enovis Corporation’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Enovis Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Enovis Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Enovis Corporation’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Enovis Corporation (ENOV) by visiting AAII Stock Evaluator.

Relative Price Strength of Enovis Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 28, 2026, Enovis Corporation has a weighted four-quarter relative price strength of -8.54%, which translates to a Momentum Score of 28 and is considered to be Weak.

Want to learn more about how Enovis Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Enovis Corporation Stock Price: Bottom Line

As of April 29, 2026, Enovis Corporation’s stock price is $22.900, which is down 2.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Enovis Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.